TY - JOUR
T1 - Generating a list of potentially important contextual factors covering randomized trials, cohorts, and measurement property studies
T2 - An OMERACT initiative
AU - Weinbrecht-Mischkewitz, Max
AU - Kamal, Midhat
AU - Asim, Farwa
AU - Guillemin, Francis
AU - Goel, Niti
AU - Voshaar, Marieke
AU - Boonen, Annelies
AU - Berthelsen, Dorthe Bang
AU - Toupin-April, Karine
AU - Lopez-Olivo, Maria A.
AU - Sloan, Victor S.
AU - Boers, Maarten
AU - Jones, C. Allyson
AU - van der Horst-Bruinsma, Irene
AU - Cashin, Aidan G.
AU - Sharma, Saurab
AU - Leong, Amye
AU - Alten, Rieke
AU - Shea, Beverley
AU - March, Lyn
AU - Contextual Factors Working Group
AU - Tugwell, Peter
AU - Christensen, Robin
AU - Nielsen, Sabrina Mai
N1 - Publisher Copyright: © 2024 The Authors
PY - 2024/4/1
Y1 - 2024/4/1
N2 - Objectives: To generate candidates for contextual factors (CFs) for each CF type (i.e., Effect Modifying Contextual Factors (EM-CFs), Outcome Influencing Contextual Factors (OI-CFs), and Measurement Affecting Contextual Factors (MA-CFs)) considered important within rheumatology. Methods: We surveyed OMERACT working groups and conducted a Special Interest Group (SIG) session at the OMERACT 2023 meeting, where the results were reviewed, and additional CFs suggested. Results: The working groups suggested 44, 49, and 21 generic EM-CFs, OI-CFs, and MA-CFs, respectively. SIG participants added 49, 44, and 55 factors, respectively. Conclusion: Candidate CFs were identified, next step is a consensus-based set of endorsed (important) CFs.
AB - Objectives: To generate candidates for contextual factors (CFs) for each CF type (i.e., Effect Modifying Contextual Factors (EM-CFs), Outcome Influencing Contextual Factors (OI-CFs), and Measurement Affecting Contextual Factors (MA-CFs)) considered important within rheumatology. Methods: We surveyed OMERACT working groups and conducted a Special Interest Group (SIG) session at the OMERACT 2023 meeting, where the results were reviewed, and additional CFs suggested. Results: The working groups suggested 44, 49, and 21 generic EM-CFs, OI-CFs, and MA-CFs, respectively. SIG participants added 49, 44, and 55 factors, respectively. Conclusion: Candidate CFs were identified, next step is a consensus-based set of endorsed (important) CFs.
KW - Arthritis
KW - Contextual factors
KW - Effect modifiers
KW - Measurement instruments
KW - OMERACT
KW - Prognostic factors
KW - Rheumatology
UR - http://www.scopus.com/inward/record.url?scp=85185176177&partnerID=8YFLogxK
U2 - 10.1016/j.semarthrit.2024.152370
DO - 10.1016/j.semarthrit.2024.152370
M3 - Article
C2 - 38290371
SN - 0049-0172
VL - 65
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
M1 - 152370
ER -